News

Kelley Presents at National Institutes of Health

Dr. Mark Kelley, Chief Scientific Officer of Apexian Pharmaceuticals, presented a special seminar at the National Institutes of Health on October 3 on his research on APX3330's effect on the Ref-1/APE signaling node in cancer and chemotherapy-induced neuropathy. In addressing the National Institute of Environmental Health Sciences, Dr. Kelley discussed the progress of this promising therapy from benchtop to the current phase 1 clinical trial.

Apexian Chief Scientific Officer Awarded $2.3 Million National Cancer Institute Grant

Research focuses on Chemotherapy-Induced Peripheral Neuropathy INDIANAPOLIS, Ind.—Apexian Pharmaceuticals’ Chief Scientific Officer, Dr. Mark Kelley, has been awarded $2.3 million by the National Cancer Institute (NCI)  to research the effects of APX3330 on chemotherapy-induced peripheral neuropathy (CIPN). CIPN affects many cancer patients and can cause severe pain, loss of feeling, balance problems, muscle weakness, and even paralysis or organ failure. The symptoms may continue years...

The Role of APE1 in Mitochondrial Metabolism

Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer related mortality in the United States, and is accompanied by a fibrotic phenotype that contributes to chemotherapeutic  resistance. Combination therapies including Gemcitabine (GemzarTM) and sustained release, nab-paclitaxel (AbraxaneTM) and FOLFIRINOX (5-FU/leucovorin/irinotecan/oxaliplatin) offer modest improvement in survival, albeit at an increase in side effects. A novel PDAC target, Apurinic/apyrimidinic endonuclease/redox factor-1 (APE1/Ref-1 or APE1) is...